Menu
Close
About Us
Company Overview
Our History
Leadership
Board of Directors
Our Advisors
Therapeutic Areas
COVID-19 and CVD
Acute Myocarditis
Heart Failure
Research
R&D Partners
Our Science
Resources
Pipeline
CardiolRX™
Investors
Events & Presentations
Press Releases
Analyst Coverage
Stock Information
Filings & Financials
Corporate Governance
Contact Us
News
Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options
March 02, 2021
Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
January 21, 2021
Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences
January 07, 2021
Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx™
December 22, 2020
Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company’s Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19
December 15, 2020
Cardiol Therapeutics’ Cortalex™ CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.
October 20, 2020
Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial
September 25, 2020
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
September 15, 2020
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx™
August 26, 2020
Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor
June 29, 2020
Page 1 of 7
1
2
3
4
5
...
»
Last »
